한글목차

세계 무균 주사제 시장 규모는 2024년 6억 1,666만 달러에서 예측 기간 동안 7.4%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 11억 7,435만 달러에 달할 것으로 예상됩니다.

만성 질환의 유병률 증가는 예측 기간 동안 무균 주사제 시장의 성장을 크게 촉진할 것으로 예상됩니다. 당뇨병, 암, 심장 질환과 같은 질병은 전 세계적으로 점점 더 널리 퍼지고 있으며, 이들 중 상당수는 지속적인 치료가 필요합니다. 예를 들어, 2023년 ICMR INDIAB의 조사에 따르면, 인도에서는 약 1억 1,000만 명이 당뇨병을 앓고 있는 것으로 보고되고 있습니다. 또한, 암은 연간 약 1,000만 명이 사망하고 있으며, 전 세계적으로 주요 건강 문제 중 하나입니다.

많은 만성 질환은 주사가 가장 효과적인 약물로 치료되는 경우가 많습니다. 이는 혈류로의 빠른 흡수, 장기간의 치료 효과 또는 특정 부위에 대한 표적 투여가 필요하기 때문입니다. 무균 주사제는 이러한 질환의 관리에 있어 중요한 역할을 하며, 효과적인 치료에 필수적인 존재입니다. 이러한 질병이 지속적으로 증가함에 따라 무균 주사제에 대한 수요는 더욱 증가하여 예측 기간 동안 시장 확대가 가속화될 것으로 예상됩니다.

세계의 무균 주사제 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 각종 부문별/지역별/주요 국가별 상세 분석, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 시장 개요와 시장 범위

제2장 주요 인사이트와 중요 포인트

• 시장 하이라이트와 전략적 포인트
• 주요 동향과 향후 예측
• 분자 유형별 개요
• 약제 유형별 개요
• 용도별 개요
• 지역별 개요

제3장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제4장 전략적 인사이트와 업계 전망

• 시장 리더와 파이오니아
• CXO의 견해
• 최신 개발과 Break through
• 사례 연구/진행 중인 연구
• 규제와 상환 상황
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 추천 전략
• 시나리오 분석 : 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석 및 가격 동향
• KOL(Key Opinion Leader)

제5장 무균 주사제 시장 : 분자 유형별

• 저분자
• 고분자

제6장 무균 주사제 시장 : 약제 유형별

• 단일클론항체
• 인슐린
• 면역글로불린
• 사이토카인
• 혈액 인자
• 기타

제7장 무균 주사제 시장 : 용도별

• 종양
• 심혈관질환
• 감염증
• 당뇨병
• 기타

제8장 무균 주사제 시장 : 지역별 시장 분석과 성장 기회

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 남미
  • 브라질
  • 아르헨티나
  • 기타
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타
• 중동 및 아프리카

제9장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도 개요와 주요 기업
• 시장 점유율 분석 및 포지셔닝 매트릭스
• 전략적 파트너십 및 M&A
• 제품 포트폴리오 및 혁신의 주요 전개
• 기업 벤치마킹

제10장 기업 개요

• Pfizer Inc.
• Amgen Inc.
• GSK Plc
• Merck &Co., Inc.
• Novartis AG
• Sanofi
• Bausch Health Companies
• Gilead Sciences, Inc.
• Hikma Pharmaceuticals P
• Cipla Inc.

제11장 가정 및 조사 방법

제12장 부록

영문목차

The global sterile injectable market reached US$ 616.66 million in 2024 and is expected to reach US$ 1,174.35 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Sterile injectables are medications or biologics that are administered through injections and are manufactured under stringent conditions to ensure they are free from any microorganisms. These products are commonly used to treat a wide range of medical conditions, especially those requiring rapid action or precise delivery to specific parts of the body. Sterile injectables are often preferred for conditions such as cancer, diabetes, autoimmune diseases, and infections.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is expected to significantly drive the growth of the sterile injectables market over the forecast period. Conditions such as diabetes, cancer, and heart disease are becoming more widespread globally, and many of these diseases require ongoing treatment. For example, the 2023 ICMR INDIAB study reported that 10.1 crore people in India are living with diabetes. Additionally, cancer is responsible for around 10 million deaths annually, making it one of the leading global health concerns.

Many chronic diseases are treated with medications that are most effective when administered through injection. This is often due to the need for rapid absorption into the bloodstream, extended therapeutic action, or targeted delivery to specific areas of the body. Sterile injectables play a critical role in managing these conditions, making them essential for effective therapy. As these conditions continue to rise, the demand for sterile injectables is expected to grow, driving market expansion during the forecast period.

High Manufacturing Costs

The high production costs associated with sterile injectables often result in higher drug prices, which can limit patient access, especially in regions with weaker healthcare infrastructure or limited insurance coverage. This creates a significant barrier for patients in need of these medications, reducing the overall market potential. Additionally, the high costs of production can cut into profit margins, leaving fewer resources available for investment in research and development (R&D) of new drugs and innovative delivery systems. This can slow the development of new treatment options and hinder the market's ability to reach new patient populations.

Unlike simpler forms of medication like tablets, sterile injectables require complex manufacturing processes to maintain sterility. This added complexity demands specialized skills, more manpower, and additional quality control measures, all of which drive up production costs. As a result, these factors are expected to limit the growth of the sterile injectables market.

Segment Analysis

The global sterile injectable market is segmented based on molecule type, drug type, application, and region.

Molecule Type:

Large molecule in the molecule type segment is expected to dominate the sterile injectable market.

The large molecules segment is expected to dominate the sterile injectable market due to their targeted approach in treating chronic diseases. These biologics are designed to precisely target specific molecules or pathways, offering more effective treatments with fewer side effects compared to traditional small-molecule drugs. Their complex structures allow for high specificity, reducing off-target effects and improving safety profiles.

Additionally, large-molecule biologics often have immunomodulatory effects, making them especially beneficial for autoimmune diseases. The ability to tailor treatment plans based on individual patient characteristics further enhances their therapeutic outcomes. These advantages are expected to maintain the segment's dominant position in the market throughout the forecast period.

Geographical Analysis

North America is expected to dominate the sterile injectable market.

North America is expected to maintain its dominant position in the sterile injectable market. North America has a strong regulatory framework that ensures the safety, efficacy, and quality of sterile injectables. Regulatory bodies like the FDA play a crucial role in approving and monitoring the use of sterile injectables, providing a secure environment for both manufacturers and consumers.

Additionally, significant investments from major market players in the region are also expected to contribute to the overall regional market growth. For instance, in February 2024, Simtra BioPharma Solutions announced a $250 million investment to expand its sterile fill/finish manufacturing campus in Bloomington, Indiana, which will include state-of-the-art facilities for high-speed automated syringe and vial filling lines.

Additionally, in June 2021, Jubilant HollisterStier, a subsidiary of Jubilant Pharmova Limited, invested $92 million to increase its sterile injectable manufacturing capacity in Spokane, WA, which will enhance production by 50%.

Alongside these investments, the growing prevalence of chronic diseases and the increasing adoption of sterile injectables are further boosting the market in the region. These factors combined are expected to solidify North America's dominant position in the sterile injectable market throughout the forecast period.

Competitive Landscape

The global market players in the sterile injectable market include Pfizer Inc., Amgen Inc., GSK Plc, Merck & Co., Inc., Novartis AG, Sanofi, Bausch Health Companies Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, and Cipla Inc., among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global sterile injectable market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Molecule Type
• 2.4. Snippet by Drug Type
• 2.5. Snippet by Application
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Prevalence of Chronic Diseases
    • 3.1.1.2. Increasing Investments and Development of New Products by Pharmaceutical Companies
  • 3.1.2. Restraints
    • 3.1.2.1. Side Effects Associated with the Sterile Injectables
    • 3.1.2.2. High Manufacturing Costs
  • 3.1.3. Opportunity
    • 3.1.3.1. Innovation in Drug Delivery Methods
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Sterile Injectable Market, By Molecule Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 5.1.2. Market Attractiveness Index, By Molecule Type
• 5.2. Small Molecule*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Large Molecule

6. Sterile Injectable Market, By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Monoclonal Antibodies*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Insulin
• 6.4. Immunoglobulin
• 6.5. Cytokines
• 6.6. Blood factors
• 6.7. Others

7. Sterile Injectable Market, By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Oncology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Cardiovascular Diseases
• 7.4. Infectious Diseases
• 7.5. Diabetes
• 7.6. Others

8. Sterile Injectable Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Amgen Inc.
• 10.3. GSK Plc
• 10.4. Merck & Co., Inc.
• 10.5. Novartis AG
• 10.6. Sanofi
• 10.7. Bausch Health Companies
• 10.8. Gilead Sciences, Inc.
• 10.9. Hikma Pharmaceuticals P
• 10.10. Cipla Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us